About US

About MediSieve

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £2M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood borne diseases. The company’s initial targets include Sepsis, Leukaemia and Malaria. Located in the new Imperial College Translation and Innovation Hub in White City, the company is preparing for first in man trials in 2019.

Latest News

MediSieve Continues Growth Trajectory with Latest Award

MediSieve Continues Growth Trajectory with Latest Award
Created on 13-11-2019

Medical device company MediSieve Ltd, has been announced as a winner of the ‘Breakthrough Medical o...
National News Coverage for MediSieve

National News Coverage for MediSieve
Created on 13-11-2019

Founder and CEO, Dr George Frodsham, speaks to the Telegraph on the birth and journey of MediSieve....